THE SHEFFIELD AREA PRESCRIBING GROUP. Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes. Date: March 2018.

Similar documents
Commissioning Statement. Flash Glucose Monitoring system (FreeStyle Libre ) March 2018

Commissioning Statement

Policy for Continuous Glucose Monitoring for Type 1 Diabetic Paediatric Patients (<18 years of age)

medicines_management/correspondence/pathway-for-the-managed- Access-of-FreeStyle-Libre.

NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system

Placename CCG. Policies for the Commissioning of Healthcare

In keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:

Policy for the Provision of Continuous Glucose Monitoring and Flash Glucose Monitoring to patients with Diabetes Mellitus

NHS Leeds CCG. Policy for the Funding of Flash Glucose Monitoring (FlashGM) in Paediatrics and Adults

Implementation of Freestyle Libre prescribing guidance across the NHS in London

FreeStyle Libre for glucose monitoring: Interim Position Statement for GPs & Patient FAQ

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) JAPC Briefing FreeStyle Libre

Description of the technology

Flash Glucose Monitoring (Flash GM) Frequently asked questions (November 2018)

Healthcare professionals involved in care of children and young people with Type 1 Diabetes Mellitus. Children and young people with diabetes mellitus

Healthcare professionals involved in care of children and young people with Type 1 Diabetes Mellitus

DIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS)

DIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS)

Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus

Country Health SA Local Health Network. Title: Continuous Glucose Monitoring (CGM) and Flash Glucose Monitoring (FGM) Ambulatory Service

Continuous Glucose Monitoring (CGM)/Real-Time Flash Glucose Scanning (FGS) Training for Healthcare Professionals and Patients

Commissioning Policy

DIABETES STRUCTURED EDUCATION IN WORCESTERSHIRE Information for Healthcare Professionals May 2011

Monitoring in Type 2 Diabetes. Learning Outcomes. Type 2 Diabetes. Senga Hunter Community Diabetes Specialist Nurse

How can I access flash glucose monitoring if I need it? Support pack. This pack will help you to find out more about flash and how you can access it.

COPYRIGHTED MATERIAL. Chapter 1 An Introduction to Insulin Pump Therapy WHAT IS INSULIN PUMP THERAPY?

Diabetes Subcommittee of PTAC meeting held 3 March (minutes for web publishing)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)

Placename CCG. Policies for the Commissioning of Healthcare

FLIPS FreeStyle Libre in Pregnancy Study

DIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS)

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?

Continuous Glucose Monitoring (CGM) Dexcom G6 Training for Healthcare Professionals and Patients

Commissioning Policy Individual Funding Request

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

University College Hospital. Blood glucose and HbA 1 c targets

Blood Glucose monitoring during extra-corporeal renal therapy and plasmapheresis.

Walsall CCG Supported Blood Glucose Meters April 2018

ssociation of Children s Diabetes Clinicians Clinicians Continuous Glucose Monitoring (CGM) Training for Healthcare Professionals and Patients

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP

Postnatal Care for Women with Type 1 or Type 2 Diabetes

DMEP Study Section 1 1

Referral to Adult Diabetes Specialist Services

Long-term effects of continuous glucose monitoring on HbA 1c levels: An audit

Corporate Medical Policy

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

Diabetes UK Consensus Guideline for Flash Glucose Monitoring

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Guidance on the Self-Monitoring of Blood Glucose in Adults with Diabetes

Standard Operating Procedure 11. Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8

Audit support for continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57)

Information leaflet for MDI patients. Improving Diabetes using Diasend

For Safe and Effective Diabetes Management

Trust Guideline for the Management of: Insulin Pump Therapy in Children with Type 1 Diabetes

Quick Reference Guide

National Paediatric Diabetes Audit

Guidance on the Self-Monitoring of Blood Glucose in Adults with Diabetes

New NICE guidance: Changes in practice for multidisciplinary teams. Part 1: Type 1 diabetes in children and young people

NDSS Helpline

Guideline for antihyperglycaemic therapy in adults with type 2 diabetes

Quick Reference Guide

QOF Indicator DM013:

How to maintain glycaemic success in adolescents using CSII Rebecca Thompson discusses how to engage with this often challenging group. Page 6.

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T

Agenda Item 10 - Glucose Monitoring Device for Individuals with Diabetes

Resources relevant for year olds

PUBLIC PETITIONS COMMITTEE AGENDA. 2nd Meeting, 2019 (Session 5) Thursday 24 January 2019

15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016

Blood Glucose Level (BGL) greater than or equal to 15.0 mmol/l

DIABETES MANAGEMENT PLAN 2019

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

DIABETES MANAGEMENT PLAN 2018

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off

Blood Glucose Level (BGL) greater than or equal to 15.0 mmol/l

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

Guidelines for managing the health care needs of children and young persons with diabetes in education

DIABETES POLICY. Mandatory Quality Area 2

THIS GUIDELINE DESCRIBES THE MANAGEMENT OF DIABETES

Policy for Supporting. Children and Young People with. Diabetes in Education

Advances in Diabetes Care Technologies

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Continuous Glucose Monitoring

Quick Reference Guide

1. Continuous Glucose Monitoring

DIABETES MANAGEMENT PLAN 2017

Updates in Diabetes Technology

Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016

DIABETES MANAGEMENT PLAN 2018

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA

State of California Health and Human Services Agency Department of Health Care Services

Diabetes group education classes

Diagnostics guidance Published: 12 February 2016 nice.org.uk/guidance/dg21

Transcription:

THE SHEFFIELD AREA PRESCRIBING GROUP Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes Date: March 2018 Overview Freestyle Libre is a flash glucose sensor device that measures *interstitial glucose. Users have a disposable sensor that is worn on the upper arm; this has a microfilament that is inserted under the skin. A reader, when passed over the sensor, displays interstitial glucose levels. The reader needs to be passed over the sensor at least every 8 hours to get continuous glucose readings. Each sensor lasts for two weeks. Each reader can store up to 90 days of data. Using Freestyle Libre should reduce the frequency of finger prick monitoring to measure blood glucose levels, however blood glucose levels should still be taken; When interstitial glucose levels are rapidly changing (due to the time lag* between blood glucose and interstitial glucose levels). To meet Driving and Vehicle Licensing Authority (DVLA) requirements. When scanned glucose results do not meet with the users symptoms. To use the bolus calculator function. When the reader indicates a low glucose reading, i.e. <4mmol/L. Sheffield has approved restricted prescribing of Freestyle Libre sensors, patient selection should be made by the specialist and as such it is amber in the traffic light drug list. Freestyle Libre should not be initiated in primary care, but prescribing may be continued after the patient has: been assessed; received training on the device; and the expected outcomes have been realised. Eligible patients should receive no more than two sensors each month (28 days) on the NHS. Below are the locally agreed criteria for patient selection for adults and children. Patients who do not fit these criteria but who wish to use the Freestyle Libre can purchase the device and sensor from Abbott directly. *Interstitial glucose levels are not quite the same as blood glucose levels, glucose levels in the blood rise and fall ahead of glucose levels in interstitial fluid. 1

Children and Young People (under 19 years of age) Criteria Paediatric patients who meet the criteria outlined within the national guideline developed by the Association of Children s Diabetes Clinicians (ACDC) will be eligible for Freestyle Libre on the NHS. The Executive summary can be found at; http://www.a-c-d-c.org/wpcontent/uploads/2012/08/cgm-fgs-executive-summary-april-2017.pdf Continuous glucose monitoring (CGM)/Freestyle Libre can be considered for children on insulin pump therapy or multiple daily injections. CGM/Freestyle Libre can be considered for improving diabetes control in children and young people by reducing HbA1c and/or reducing the time spent in hypoglycaemia, with any HbA1c <10% (<85 mmol/mol). CGM/Freestyle Libre may be used where fear of hypoglycaemia provokes clinically significant anxiety and is a barrier to good control. Frequent hypoglycaemia and in nocturnal hypoglycaemia. Note - Freestyle Libre may be considered where hypoglycaemia or hypoglycaemia unawareness is a problem but in many circumstances a full CGM system with alarms may be more suitable. The Freestyle Libre may be considered in certain circumstances where capillary blood glucose monitoring within the school or nursery environment is challenging and adversely affecting control (note training will be given to the school). Continuous CGM/Freestyle Libre should be considered for exercise in children and young people in the following circumstances: o For those competing or exercising regularly. It can be used to optimise carbohydrate and insulin adjustment before, during and after exercise to maximise the effect of exercise on improving diabetes control and ensure that sporting performance is optimised. o For adolescents trying to lose weight but fearful of the hypoglycaemic effects of exercise. o For those who have had a severe episode of hypoglycaemia following sporting activity and cannot resume activity. o For those in whom there is concern regarding overcompensation with additional carbohydrate for activity. o Those involved in high endurance sporting activities where it is difficult to test blood sugar. o For those where exercise results in unpredictable hypoglycaemia. Where clinically appropriate, Freestyle Libre may be considered in patients doing more than 6 capillary blood tests daily as likely to be cost neutral. In order to maximise benefit patients must use the device at least 70% of the time (5/6 days a week minimum). Ideally it should be used continuously. The use of Freestyle Libre should be used to bring about clinical benefits. Whilst a reduction in capillary glucose testing would be expected, capillary blood glucose testing will still be needed in certain situations (see above). The use of the Freestyle Libre should not be seen as a direct alternative or replacement for capillary glucose testing. All patients will have a defined trial period of the Freestyle Libre (see criteria for stopping below); attendance at specific teaching/training sessions is a key pre-requisite of NHS provision of Freestyle Libre systems. Primary care will be asked to prescribe after training has been received and the trial period completed. The specialist will continue to monitor effectiveness and advise the GP on continued need. 2

Criteria for stopping in children and young people. Withdrawal Freestyle Libre funding should be withdrawn in the following situations: After 1 month if: o CGM has not been used 70% of the time 5/6 days a week minimum o Family have not attended all 4 education step 1,2,3,4 sessions unless extenuating circumstances At 3 months if: o Not worn for at least 5 days a week. o No improvement in any of the following factors Glycaemic control HbA1c improved by >0.5% if it was >7.5% (58 mmol/mol) at start of CGM therapy No improvement in scores on fear of hypoglycaemia scales where CGM was introduced for anxiety No reduction in frequency of hypoglycaemia particularly nocturnal hypoglycaemia (assessed from CGM download) 3

Adults Criteria Type 1 diabetes patients and willing to engage with secondary care team on a regular basis, as evidenced by regular appointment attendance, diary completion, baseline and follow-up assessment of HbA1c etc. Ongoing self-care and management as evidenced by all 9 care processes being up to date (see appendix). o PLUS one or more of the following: Type 1 diabetes patients on basal bolus or pump therapy with sub optimal control i.e. HbA1c > 8.5% (69mmol/mol), DAFNE trained and engaging in self-management, i.e. testing on average 4 times a day for 3 months as evidenced by a meter download Planning pregnancy or pregnant (hypoglycaemia awareness is reduced in pregnancy) Frequent episodes of hypoglycaemia/diabetic ketoacidosis needing DSN (diabetes specialist nurse) support Patients with learning difficulties sufficient to impede SMBG or palliative patients Patient monitoring blood glucose 8 or more times a day Patients already self-funding and achieving an HbA1c of <59mmol/mol, blood glucose in target most of the time, with <10% of readings under 4mmol/L. Primary care will be asked to prescribe after 12 months, after training has been received, and impact of using the Freestyle Libre has been assessed. Groups not suitable Individuals with total hypoglycaemia unawareness Individuals with HbA1c >85mmol/mol (indicating not giving insulin regularly each day) Criteria for stopping Patients with a baseline HbA1c <70mmol/mol - if a 5mmol/mol drop by 3 months is not achieved or a significant reduction in time spent in hypoglycaemia is not achieved. If reduction not maintained at 6 months. Patients with a baseline HbA1c 70mmol/mol - if a 10mmol/mol drop by 3 months is not achieved. If reduction is not maintained at 6 months. For those previously self-funding blood glucose levels - not at target for the majority of time, HbA1c >58mmol/mol or >10% of readings under 4mmol/L Not up to date with the 9 care processes Further supporting information Community pharmacies need to order Freestyle Libre directly from Abbott, see link to the dedicated web portal - www.freestylediabetes.co.uk/pharmacy 4 An account needs to be set up (takes 24 hours), then ordered stock is delivered free of charge directly to them on the next working day.

Appendix - The nine processes of care; Weight Blood pressure Smoking status HbA1c. Urinary albumin Serum creatinine Cholesterol Eye examinations. Foot examinations. This position statement was developed in conjunction with diabetes specialists at STHFT and SCHFT and approved by APG January 2018. Review January 2019, minor amendment March 2018 5